Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial

Gschwend, JE; Bajorin, D; Galsky, M; Broughton, E; Braverman, J; Koon, H; Maira-Arce, M; Hamilton, M; Shi, L; Guo, S; Witjes, JA

EUROPEAN UROLOGY, 2021; 79 (): S1139